Clinical roles of plasma phosphatidylcholine hydroperoxide-reducing activity in the development of pre-eclampsia

点击翻译按钮获取中文摘要

Plasma lipid peroxide has been known as risk factor for atherogenesis, because lipid peroxide attacks endothelial cells. We found that blood plasma possess lipid peroxide reducing activity other than plasma glutathione peroxidase, a major lipid peroxide reducing enzyme. In this study, we initially purified this lipid peroxide reducing protein from human blood plasma and successfully isolated apolipoprotein A1 and B100 as phosphatidylcholine hydroperoxide reducing proteins. In order to clarify the pathophysiological roles of the activity, we have developed an assay method to measure plasma phosphatidylcholine hydroperoxide reducing activity using synthetic 1-pdtoyl-2-nnoleoyl-phosphatidylchonne hydroperoxide (PLPC-OOH) as the substrate. By using this method, PLPC-OOH reducing activity was determined in the plasma of 53 normal pregnancies, 11 patients of pre-eclampsia, 18 pre-stage and 11 high-risk groups for pre-eclampsia. PLPC-OOH reducing activity was greater in the high-risk group than normal pregnancy, while lipid peroxide level was greater in the pre-eclamptic patients. The present results suggested an important role(s) for PLPC-OOH reducing activity in elimination of the plasma lipid hydroperoxide, and further involvement in the development of pre-eclampsia.